Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure (NCT05598333)
A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multi-center Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of AB-1002 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic Cardiomyopathy
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age \>18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF. Subjects will be randomized into one of three treatment groups in a 1:1:1
Who can join: Review the eligibility criteria below.
Location: Cardiology P.C. Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (96 Sites)
Showing the first 25 of 96 sites.
- Cardiology P.C. Birmingham — Birmingham, Alabama
- University of Arizona Sarvor Heart Center — Tucson, Arizona
- University of California Irvine Medical Center — Irvine, California
- University of California San Diego — La Jolla, California
- University of California San Francisco — San Francisco, California
- Baycare Medical Group — Clearwater, Florida
- University of Miami — Coral Gables, Florida
- University of Florida — Gainesville, Florida
- Augusta University — Augusta, Georgia
- Loyola Medicine Burr Ridge — Oakbrook Terrace, Illinois
- University of Iowa — Iowa City, Iowa
- University of Kansas Medical Center (KUMC) — Kansas City, Kansas
- Massachusetts General Hospital — Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts
- Minneapolis Heart Institute Foundation — Minneapolis, Minnesota
- Mayo Clinic - Minnesota — Rochester, Minnesota
- Aurora Saint Luke's Health System — Kansas City, Missouri
- St. Louis University — St Louis, Missouri
- Renown Health — Reno, Nevada
- Morristown Medical Center - Cardiology — Morristown, New Jersey
- Mt. Sinai New York — New York, New York
- Stony Brook — Stony Brook, New York
- Montefiore Medical Center — The Bronx, New York
- Duke University — Durham, North Carolina
- The Christ Hospital / The Linder Center for Research — Cincinnati, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Congestive Heart Failure
- SyncAV Post-Market Trial — Huntsville, Alabama
- Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study — Boston, Massachusetts
- Boston Medical Center Ultrasound Decongestion Study in Heart Failure — Boston, Massachusetts
- Palliative Care for People With HF — Indianapolis, Indiana
- Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease — Murray, Utah
Explore by condition: All Congestive Heart Failure clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.